Phase I Trial of Two Schedules of Vincristine, Oral Irinotecan, and Temozolomide (VOIT) for Children with Relapsed or Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Study

BACKGROUND: In pre-clinical models, temozolomide and vincristine are additive or synergistic with irinotecan. We examined this 3-drug combination in children with relapsed solid tumors. Patients received orally administered irinotecan together with temozolomide and vincristine on two different sched...

詳細記述

保存先:
書誌詳細
主要な著者: Wagner, Lars M., Perentesis, John P., Reid, Joel M., Ames, Matthew M., Safgren, Stephanie L., Nelson, Marvin D., Ingle, Ashish M., Blaney, Susan M., Adamson, Peter C.
フォーマット: Artigo
言語:Inglês
出版事項: 2010
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3074342/
https://ncbi.nlm.nih.gov/pubmed/20049936
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.22407
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料